SK CHEMICALS CO., LTD.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: Dapoxetine 30mg tablet
Drug: Mirodenafil 50mg tablet

First Posted Date: 2015-06-30

Last Posted Date: 2015-06-30

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT02485028

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg

Phase 1

Completed

Conditions: Drug Interaction Potentiation

Interventions: Drug: Dapoxetine 30mg
Drug: Mirodenafil 100mg

First Posted Date: 2015-06-30

Last Posted Date: 2015-06-30

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT02485041

Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: THVD-201
Drug: Placebo(For Detrusitol 2mg tablet)
Drug: Placebo(For THVD-201)
Drug: Detrusitol 2mg tablet

First Posted Date: 2015-06-30

Last Posted Date: 2017-01-12

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 384

Registration Number: NCT02485067

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
The Catholic University of Korea, Bucheon ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Korea, Republic of

and more 13 locations

Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: NBP607-V
Biological: NBP607-QIV
Biological: NBP607-Y

First Posted Date: 2015-06-10

Last Posted Date: 2020-05-08

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 1503

Registration Number: NCT02467842

Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: Agrippal S1
Biological: NBP607

First Posted Date: 2015-01-22

Last Posted Date: 2015-01-22

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 1155

Registration Number: NCT02344134

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670

Phase 1

Completed

Conditions: Endometriosis

Interventions: Drug: SKI2670
Drug: Placebo

First Posted Date: 2014-07-29

Last Posted Date: 2017-10-20

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT02202408

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Immunogenicity and Safety Study of NBP606 in Healthy Infants

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: NBP606
Biological: Prevnar13

First Posted Date: 2014-07-25

Last Posted Date: 2020-04-20

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 577

Registration Number: NCT02201030

Locations: 🇰🇷
Confidential, Seoul, Korea, Republic of

Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation

Phase 2

Completed

Conditions: Constipation
Irritable Bowel Syndrome

Interventions: Drug: YKP10811 20mg
Drug: YKP10811 placebo
Drug: YKP10811 5mg

First Posted Date: 2014-03-10

Last Posted Date: 2015-06-12

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 273

Registration Number: NCT02082457

Locations: 🇰🇷
Gang Nam Severance Hospital, Gang Nam Gu, Seoul, Korea, Republic of

Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Non-constipation Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: SKI3246 High Dose
Drug: SKI3246 Low Dose

First Posted Date: 2014-03-06

Last Posted Date: 2015-06-01

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 279

Registration Number: NCT02079675

Locations: 🇰🇷
SK Chemicals, Seoul, Korea, Republic of

Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine

Phase 3

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: Prodiax-23
Biological: NBP606

First Posted Date: 2014-03-05

Last Posted Date: 2016-01-27

Lead Sponsor: SK Chemicals Co., Ltd.

Target Recruit Count: 767

Registration Number: NCT02079207

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy